Short Interest in NPS Pharmaceuticals Expands By 45.3% (NPSP)
NPS Pharmaceuticals (NASDAQ:NPSP) was the target of a large increase in short interest in the month of May. As of May 15th, there was short interest totalling 11,896,553 shares, an increase of 45.3% from the April 30th total of 8,186,514 shares, ARN reports. Currently, 12.1% of the company’s shares are sold short. Based on an average daily volume of 2,916,450 shares, the days-to-cover ratio is presently 4.1 days.
NPSP has been the subject of a number of recent research reports. Analysts at Janney Montgomery Scott initiated coverage on shares of NPS Pharmaceuticals in a research note on Thursday, May 22nd. They set a “buy” rating and a $37.00 price target on the stock. Separately, analysts at Zacks reiterated an “outperform” rating on shares of NPS Pharmaceuticals in a research note on Tuesday, May 13th. They now have a $33.00 price target on the stock. Finally, analysts at Leerink Swann reiterated an “outperform” rating on shares of NPS Pharmaceuticals in a research note on Friday, May 9th. They now have a $40.00 price target on the stock, down previously from $47.00. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $38.80.
NPS Pharmaceuticals (NASDAQ:NPSP) opened at 27.45 on Friday. NPS Pharmaceuticals has a 1-year low of $14.06 and a 1-year high of $39.68. The stock has a 50-day moving average of $26.22 and a 200-day moving average of $29.8. The company’s market cap is $2.919 billion.
NPS Pharmaceuticals (NASDAQ:NPSP) last released its earnings data on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.04. The company had revenue of $44.04 million for the quarter, compared to the consensus estimate of $48.30 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share. The company’s revenue for the quarter was up 73.2% on a year-over-year basis. Analysts expect that NPS Pharmaceuticals will post $0.02 EPS for the current fiscal year.
NPS Pharmaceuticals, Inc (NASDAQ:NPSP) is a biopharmaceutical company focused on pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.